Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3900_Библиотеки_им_академика_М_И_Перельмана
.pdf
378 Index
Endovascular aortic aneurysm repair (contiued)
of thoracic aortic aneurysms
aortic arch, 348–349
aortic tortuosity, 344–347
arterial access, 343–344
neurological complications, 348
stent-graft sizing, 347
thoracoabdominal aorta, 349–350
Endovascular ruptured aneurysm repair,
109–110
Esophagogastroduodenoscopy, 240
European Collaborators on Stent Graft
Techniques for Abdominal Aortic
Aneurysm Repair (EUROSTAR) registry,
123, 125, 127, 209
EVAR, see Endovascular aortic aneurysm repair
EVrAR, see Endovascular ruptured aneurysm repair
Excluder endograft, 124
Expression profiling, 14–17
External iliac artery, 170–171, 175–177
Extracellular matrix, 27
proteins, 30
F
False aneurysms (FAs), 142–143
Fenestrated endovascular stent-grafts, 110–111
current applications, 153–156
evolution of technique, 151–153
for juxtarenal, suprarenal and thoracoabdominal
aneurysms, 153–155
limitations of technique, 156
outcomes, 156–157
principles and technique, 150–151
reinforced, 111
See also Endovascular aortic aneurysm repair
Fibronectin, 29
Food and Drug Administration (FDA), 199–200
G
Gadolinium-based contrast agents, 45–46, 51
Gene ontology (GO), 14, 30
Genomic control method, 8
Glasgow Aneurysm Score (GAS), 188
Graft enteric fistula, 144
H
HA, see Hypogastric artery
Hardman index, 188
Hardy-Weinberg equilibrium, 31
Human leukocyte antigen (HLA), 8
Hypogastric artery, 170–171
aneurysms, 359–360
interruption during EVAR, effects of
bowel ischemia after EVAR, 174
buttock claudication (BC), 173–174
occlusion, during EVAR, 174–176
perfusion, preservation of, 176–177
Hypothermia, 192
I
IBDs, see Iliac bifurcated devices
IIA, see Internal iliac artery
IL-1 α, see Interleukin-1 alpha
IL1B, 15
Iliac artery aneurysms
diagnostic evaluation, 354–355
epidemiology, 353–354
natural history and risk of rupture, 354
repair of, 355
endoluminal, 356
surgical, 356
Iliac bifurcated devices, 177
Indium-labeled WBC scan, 229
Inferior mesenteric artery (IMA), 51, 80, 85,
87, 101, 107–108, 170–174, 257–259,
326–331, 333
Inferior vena cava
embryology, 289–291
venous anomalies
azygos continuation, vena caval interruption
with, 300–301
duplicated vena cava, 298–300
epidemiology of, 292–293
general principles in management of, 305
infrarenal cava, absence of, 301–304
left-sided vena cava, 296–298
marsupial cava, 301
multiple, 304–305
retroaortic and circumaortic left renal vein,
293–295
Infrarenal cava, absence of, 301–304
Initial preventative physical examination
(IPPE), 60
Interleukin-1 alpha, 29
Internal iliac artery, 170–174, 176–178
coil embolization of, 175
International Society for Cardiovascular Surgery
guidelines, 96
Intravascular ultrasound (IVUS), 35,
50–53, 102
IVC, see Inferior vena cava
J
Juxtarenal/suprarenal AAAs and thoraco-abdominal
aneurysms, 253
directional branch endografts, 111
fenestrated endografts, 110–111, 153–155
open surgical treatment of, see Pararenal AAAs,
open surgical treatment of
reinforced fenestrated endografts, 111
https://t.me/med1917
Index 379
K
Kaplan-Meier analysis, 123–124
k-Space data, 43
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway, 14–15, 30
L
Laminen, 29
Left internal mammary artery (LIMA) coronary
bypass, 345
Left-sided vena cava, 296–298
Lifeline Registry of Endovascular Aneurysm
repair, 125
Logarithm of odds (LOD) score, 6
Lunderquist, 344
Lymphocele, 143
M
Macrolides, 64
Magnetic resonance imaging, 43–50, 285, 354
aortic graft infections and, 228
to diagnose RAAA, 185
Marfan’s syndrome, 2, 27, 63–64
Marsupial cava, 301
MAS, see Mesenteric artery stenosis
Matrix metallopeptidases, 8, 15, 17–19, 28–29
inhibition, by tetracycline antibiotics, 64–65
MMP-9, 62
Maximal potential rupture rate, 98
May-Thurner syndrome, 297
MDCT, see Multidetector CT scanners
Mesenteric artery stenosis, 250
and aortic aneurysms
combination approaches for, 260
endovascular options for, 259–260
intervention on, 257–258
open surgical options for, 259
prevalence, 255–257
Mesenteric ischemia, AAA repair and, 325
arterial anatomy, 326
diagnosis and management, 331–332
etiology
anatomic, 326–328
embolic and mechanical, 328
physiologic, 328–331
IMA, treatment of, 333
internal iliac arteries, treatment of, 333–334
preoperative planning, 333
MFS, see Marfan’s syndrome
MMPs, see Matrix metallopeptidases
MODS, see Multiple Organ Dysfunction Score
MPRR, see Maximal potential rupture rate
MRI, see Magnetic resonance imaging
Multicentre Aneurysm Screening Study, 73
Multidetector CT scanners, 38–40
Multiple Organ Dysfunction Score, 189
Mycotic aneurysms
clinical presentation, 218–219
diagnosis and imaging, 219–220
outcomes, 224–225
pathogenesis, 218
treatment, 220–224
N
N -acetylcysteine, 51
National Heart, Lung, and Blood Institutes
(NHLBI), 63
National Hospital Discharge Survey database, 198
National US Medicare database (1999–2003), 110
Nephrogenic systemic fibrosis, 46
Nitric oxide synthase 3 (NOS3), 8, 14
O
Online Mendelian Inheritance in Man (OMIM)
database, 7
Open aortorenal endarterectomy, 252
Open operative therapy, for RAAA, 183
abdominal closure after
late survival, 193
postoperative management, 192–193
clinical presentation, 184–185
operative strategy
distal control, 191
operation, 192
proximal control, 190–191
resuscitation and transfer, 185–188
risk scoring
Canadian Society for Vascular Surgery
Aneurysm Study Group, 189
Glasgow Aneurysm Score (GAS), 188
Hardman index, 188
Multiple Organ Dysfunction Score (MODS), 189
POSSUM, 188–189
Vancouver Scoring System (VSS), 189
Open versus Endovascular Repair (OVER) trial, 126
P
PAAs, see Popliteal artery aneurysms
Pararenal AAAs, open surgical treatment of
clinical presentation, 159–163
operative technique, 163–165
surgical outcomes, 166
Paresis/paraplegia, 212
Penile brachial pressure index (PBI), 172
Physiological and Operative Severity Score for
Enumeration of Mortality and Morbidity,
188–189
PIVOTAL trial, 129
https://t.me/med1917
380 Index
Pleiotropic effects, 62
Polytetrafluoroethylene (PTFE) grafts, 244, 258, 304
Popliteal artery aneurysms, 363
demographics, 364
diagnosis, 364–366
nonoperative treatment, 372
pathogenesis, 364
presentation and indications for repair, 366–368
thrombolysis for acute ischemia, 371–372
treatment, 368–370
POSSUM, see Physiological and Operative Severity
Score for Enumeration of Mortality and
Morbidity
Postimplant syndrome, 139, 211–212
Precontrast images, 38
Primary percutaneous angioplasty (PTA), 251
Pyloric stenosis, 2
R
Randomized clinical trials (RCTs), 59, 63–64,
98, 208
ADAM trial, 129
DREAM trial, 127
EVAR clinical trial, 126
OVER trial, 126
PIVOTAL trial, 129
UK EVAR trials, 127–128
UK Small Aneurysm trial, 129
RAS, see Renal artery stenosis
Renal artery bypass, 252–253
Renal artery stenosis, 249–251
and aortic aneurysm, management of
combination approaches for, 254–255
endovascular options for, 253–254
open surgical repair of, 251–253
Renal ectopia/fusion, AAA in patient with
background and prevalence, 263–264
classification, 264–269
complications, 274–275
diagnosis and imaging, 269–270
embryology, 264
endovascular repair, 273–274
open repair, 270–273
Renovascular hypertension, 250–251
Retroperitoneal approach, for AAAs repair, 82
Rituximab, 279
RUNX3, 15
Ruptured AAA, endovascular repair of, 197
anatomic canadacy for, 199–200
complications, early and late, 201–203
abdominal compartment syndrome (ACS), 211
acute conversion to open repair, 210–211
acute renal failure, 212
delayed conversion to open repair, 213
endoleak, 209–210, 213
graft infection, 213
graft thrombosis, 213
mortality, 208
paresis/paraplegia, 212
postimplant syndrome, 211–212
technical failure, 209
visceral ischemia/bowel infarction, 211
preoperative evaluation and management,
198–199
published outcomes, 203–204
technical considerations, 200–201
Ruptured AAA, open operative therapy for, 183
abdominal closure after
late survival, 193
postoperative management, 192–193
clinical presentation, 184–185
operative strategy
distal control, 191
operation, 192
proximal control, 190–191
resuscitation and transfer, 185–188
risk scoring
Canadian Society for Vascular Surgery
Aneurysm Study Group, 189
Glasgow Aneurysm Score (GAS), 188
Hardman index, 188
Multiple Organ Dysfunction Score (MODS),
189
POSSUM, 188–189
Vancouver Scoring System (VSS), 189
Russell bodies, 28
RVH, see Renovascular hypertension
S
Screening for Abdominal Aortic Aneurysms Very
Efficiently (SAAAVE) Amendment, 59
SERPINE1 gene (plasminogen activator inhibitor 1),
14
SF-36 Health Survey, 60
SFV, see Superficial femoral vein
Sib-pair approach, 5–6
SIRS, see Systemic inflammatory response syndrome
Slip-ring technology, 37
SMA, see Superior mesenteric artery
Society for Vascular Surgery guidelines, 96
SOST, 15
Spinal cord, colonic, and pelvic ischemia, 143–144
Staphylococcal species, graft infection and, 225–226
Statin therapy, 62–63
Superficial femoral vein, 223
Superior mesenteric artery, 170, 326–329, 333
Supracardinal veins, 290–291
Systemic inflammatory response syndrome, 218–219
https://t.me/med1917
Index 381
T
TAAAs, see Thoraco-abdominal aortic aneurysms
TAG stent-graft, 344
T-bar effect, 107
T-cell-mediated acute cellular rejection,
278–279
See also Transplant patients, AAA in
Tetracycline antibiotics, as MMP inhibitors,
64–65
TGF- β, see Transforming growth factor-beta
Thigh claudication (TC), 169
Thoracic aortic aneurysms
and dissections (TAAD), 7
endovascular repair of
aortic arch, 348–349
aortic tortuosity, 344–347
arterial access, 343–344
neurological complications, 348
stent-graft sizing, 347
thoracoabdominal aorta, 349–350
Thoraco-abdominal aortic aneurysms,
349–350
Juxtarenal/suprarenal AAAs and
directional branch endografts, 111
fenestrated endografts, 110–111
reinforced fenestrated endografts, 111
operative therapy for, 337
hybrid repair, 340–341
open repair, 339–340
postoperative management, 341
preoperative evaluation, 338–339
Thrombosis, 142
Time-of-flight (TOF) imaging, 46
Timp1 gene, 14
Tissue inhibitors of metallopeptidases
(TIMPs), 8, 17–19
Tissue oxygenation index, 172
TNF- α, see Tumor necrosis factor-alpha
Tobacco smoking, AAA disease and, 61–62
TOI, see Tissue oxygenation index
Transforming growth factor-beta, 27, 29–30
Transplant patients, AAA in, 277
pathophysiology
immunosuppressive medications, 278–279
inflammation, modulation of, 279–280
posttransplant hemodynamics, 280
perioperative period, immunosuppression
management in, 281–282
prevalence and screening of, 280–281
repair of
planning of, 282–283
technical considerations of, 283–286
T1/T2-weighted images, 44–45, 45, 228
Tumor necrosis factor-alpha, 31
TX2 Superflex delivery system, 344, 346
U
UK registry for Endovascular Treatment for
Aneurysm (RETA), 125, 127
UK Small Aneurysm trial, 73, 97–98, 129
Ultrasonography screening, 5
V
Vancouver Scoring System (VSS), 189
Vinyon-N grafts, 72
Z
Zenith endograft, 123–124, 254, 349
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана